Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.

about

Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Safety of high-dose daptomycin in patients with severe renal impairment.

P2860

Q38907793-27072744-61E9-4875-BB6E-68899DAC3A1F Q54120294-17376903-8795-40E9-8C33-2D6714C2530B

P2860

Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.

Item

http://www.wikidata.org/entity/Q38164685

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Daptomycin dosing strategies i ...... kly intermittent hemodialysis.

@en

type

Item

label

Daptomycin dosing strategies i ...... kly intermittent hemodialysis.

@en

prefLabel

Daptomycin dosing strategies i ...... kly intermittent hemodialysis.

@en

P1476

Daptomycin dosing strategies i ...... kly intermittent hemodialysis.

@en

P2093

Molly Haselden

http://www.w3.org/2001/XMLSchema#string

Molly Leach

http://www.w3.org/2001/XMLSchema#string

Nicole Bohm

http://www.w3.org/2001/XMLSchema#string

P2860

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells

Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

In vivo pharmacodynamic activity of daptomycin

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

P304

1342-1347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028013503110

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24259698

http://www.w3.org/2001/XMLSchema#string

Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.

about

P2860

P2860

Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698